0001193125-19-291051 Sample Contracts

Cytokinetics, Incorporated, Issuer AND U.S. Bank National Association, Trustee INDENTURE Dated as of November 13, 2019 Debt Securities
Indenture • November 13th, 2019 • Cytokinetics Inc • Pharmaceutical preparations • New York

INDENTURE, dated as of November 13, 2019, among CYTOKINETICS, INCORPORATED, a Delaware corporation (the “Company”), and U.S. BANK NATIONAL ASSOCIATION, as trustee (the “Trustee”):

AutoNDA by SimpleDocs
CYTOKINETICS, INCORPORATED UNDERWRITING AGREEMENT
Cytokinetics Inc • November 13th, 2019 • Pharmaceutical preparations • New York
SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT
Loan and Security Agreement • November 13th, 2019 • Cytokinetics Inc • Pharmaceutical preparations

THIS SECOND AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of November 7, 2019, by and between OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 of the Loan Agreement (as defined below) or otherwise party thereto from time to time (each a “Lender” and collectively, the “Lenders”) including Oxford in its capacity as a Lender and SILICON VALLEY BANK, a California corporation with an office located at 3003 Tasman Drive, Santa Clara, CA 95054 (“Bank” or “SVB”) (each a “Lender” and collectively, the “Lenders”), and CYTOKINETICS, INCORPORATED, a Delaware corporation with offices located at 280 East Grand Avenue, South San Francisco, CA 94080 (“Borrower”).

CYTOKINETICS, INCORPORATED and U.S. BANK NATIONAL ASSOCIATION as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of November 13, 2019 4.00% Convertible Senior Notes due 2026
Cytokinetics, Incorporated • November 13th, 2019 • Cytokinetics Inc • Pharmaceutical preparations • New York

THIS SUPPLEMENTAL INDENTURE, dated as of November 13, 2019 (the “Supplemental Indenture”), to the Indenture, dated as of November 13, 2019 (the “Base Indenture” and, as amended, modified and supplemented by this Supplemental Indenture, the “Indenture”), between Cytokinetics, Incorporated, a Delaware corporation, as issuer (the “Company”) and U.S. Bank National Association, as trustee (the “Trustee”).

FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT
Loan and Security Agreement • November 13th, 2019 • Cytokinetics Inc • Pharmaceutical preparations

THIS FIRST AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of November 6, 2019, by and between OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 of the Loan Agreement (as defined below) or otherwise party thereto from time to time (each a “Lender” and collectively, the “Lenders”) including Oxford in its capacity as a Lender and SILICON VALLEY BANK, a California corporation with an office located at 3003 Tasman Drive, Santa Clara, CA 95054 (“Bank” or “SVB”) (each a “Lender” and collectively, the “Lenders”), and CYTOKINETICS, INCORPORATED, a Delaware corporation with offices located at 280 East Grand Avenue, South San Francisco, CA 94080 (“Borrower”).

Time is Money Join Law Insider Premium to draft better contracts faster.